How semaglutide works across the body

A 2026 review in Expert Review of Clinical Pharmacology takes a step back from the trial headlines and asks a harder question about semaglutide: not just whether it works, but how its effects ripple across the body at the molecular level. The author frames it as a systems medicine view, meaning the drug is read as one input that touches many organs and signalling pathways at once rather than a single switch with a single output^[1]. This explainer walks through that picture in plain English, and is careful to separate what the trials have settled from what the molecular mapping is still working out.

What semaglutide is, in one paragraph

Semaglutide is a GLP-1 receptor agonist, a drug that mimics glucagon-like peptide-1, a hormone the gut releases after you eat that tells the pancreas to release insulin and the brain that you are full. The European Medicines Agency describes it acting "in the same way as GLP-1," and it is authorised in the EU for type-2 diabetes as a prescription-only medicine made by Novo Nordisk^[2]. The review uses that receptor action as the starting point and then traces the downstream effects outward from there.

Why one drug touches several systems

GLP-1 receptors are not confined to the pancreas. They sit in the gut, in the appetite-regulating regions of the brain, and on cells throughout the cardiovascular and metabolic systems, which is why a single receptor agonist produces effects in more than one place. The review reports that semaglutide delivers improvements in glycemic control, weight loss, and cardiovascular protection, and that its actions reach across multiple organs rather than staying local to glucose handling^[1]. That breadth is the whole reason a systems lens is useful here. The appetite effect is mostly central, driven by GLP-1 receptors in the brain regions that govern hunger and fullness, while the glucose effect runs through the pancreas and the cardiovascular effect through the heart and vessels. One receptor, several destinations.

The clinical trial record backs each of those three effects directly. In the STEP-1 obesity trial, semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks, against 2.4% on placebo, with both groups receiving the same lifestyle support.

On the cardiovascular side, the SELECT trial enrolled 17,604 adults with overweight or obesity and existing heart disease but no diabetes, and reported a 20% reduction in major adverse cardiovascular events, a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke, with a hazard ratio of 0.80^[3]. STEP-1 supplies the weight figure^[4], and the two trials together are why the review can describe the drug as working on body weight and on the heart at the same time.

The molecular layer the review focuses on

Where the review goes beyond the familiar trial numbers is the molecular signalling underneath them. It points to mediators including adiponectin, fibroblast growth factor 21 (FGF21), apolipoprotein C-III (ApoC-III), ceramides, and extracellular-matrix remodelling proteins, and links changes in these to improved insulin sensitivity, reduced fat-tissue inflammation, and restored metabolic flexibility^[1]. In plain terms, these are the biochemical go-betweens that may help explain why the whole-body effects show up the way they do.

This is the part to hold loosely. Naming a mediator that moves in the same direction as a clinical benefit is not the same as proving it causes that benefit. The review itself leans on artificial intelligence and machine learning to connect these biomarkers to clinical outcomes, which is a sign the field is still mapping the links rather than treating them as settled. The mechanism story is partly drawn, not finished.

How to read a systems claim without overclaiming

The honest summary is that the clinical outcomes are strong and the molecular map is a work in progress. Semaglutide has a well-characterised receptor mechanism and large randomised trials behind its glucose, weight and cardiovascular effects. The cross-system molecular detail is an active research area, and a single review synthesising it is a useful map, not a final verdict. For the receptor mechanism, dosing context and the full trial list, our semaglutide overview is the next stop, and our regulatory status by country covers where it is prescription-only.

None of this is medical advice, and none of it is a dosing instruction. Semaglutide is a prescription-only medicine everywhere we cover. If you are weighing it up, the conversation that matters is with a clinician who knows your history.